Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27-08-2019
txking / iStockphoto.com
Global biopharmaceutical company Celgene Corporation, headquartered in New Jersey, has filed a claim against oncology company Beacon Pharmaceuticals, situated in Bangladesh, for trademark infringement.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Intellectual property, Celgene, Beacon, trademark infringement, Otezla, apremilast
